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ABSTRACT 
 
 
Tangeman, Lorraine Susan. M.S., Department of Biological Sciences, Wright State 
University, 2013.  Can Antibiotics From Recently Discovered Marine Actinobacteria 
Slow The Tide of Antibiotic Resistance? 
 
 
Actinobacteria, one phylum of gram positive bacteria, are found throughout all the 
environments on earth.  Actinobacteria have long been studied for the benefits they 
provide, both to their environment and to humans, and have a great capacity for 
adaptation and evolution.  They decompose organic matter, replenishing nutrients into the 
soil, and as such are important members of the food chain.  Humans benefit from the 
exploitation of Actinobacterial metabolites as antimicrobial drugs.  These antimicrobials 
have been effectively utilized for decades in the fight against infectious disease.  Despite 
the success of this drug arsenal we are now in the midst of an epidemic of multidrug-
resistant superbugs that render established drugs ineffective.  In order to find new 
antimicrobial drugs, researchers have turned to the recent discovery of several new 
species of marine Actinobacteria and analyzed their metabolites for antimicrobial 
activity.  Several metabolites were effective in vitro, and may lead to the development of 
marketable pharmaceuticals. 
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I.  INTRODUCTION 
 
For the past 70 years, we have lived in a period when humans believed infectious disease 
was able to be conquered.  In 1900, infectious diseases claimed the lives of 
approximately 1 in 100 Americans, and by 2000, that number was reduced to 1 in 300 
(Black, 2012).  This change is due in part to the discovery and subsequent widespread 
administration of antimicrobial drugs.  These drugs, called antibiotics, have been 
considered miracle drugs and have contributed to the increase in life expectancy of 
Americans from 40 years in 1850 to nearly 80 years today (Black, 2012).  A few 
antibiotics are synthetic antibiotics and are completely man-made.  Some are 
semisynthetic antibiotics which are natural antibiotics that have been chemically altered 
by humans to make them more effective and/or able to withstand microbial resistance 
mechanisms. 
 
Most antibiotics are natural substances, produced through metabolic processes of bacteria 
in the genera Streptomyces and Bacillus (phylum Actinobacteria) or from fungi in the 
genera Penicillium and Cephalosporium.  These substances are called secondary 
metabolites. Actinobacteria are best known for their production of secondary metabolites, 
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which are secreted cellular molecules that have been exploited by humans as 
pharmaceutical chemicals.  Many antibiotics, anti-cancer drugs, anti-viral drugs, and 
other medicines have been derived from Actinobacteria.  The genes for these metabolites 
are induced when the culture encounters nutrient depletion and/or growth rate decrease, 
and are understood to play a role in regulating the growth of competitors for space and 
nutrients.  These metabolites may serve as quorum sensing molecules, fostering 
communication between species in an ecosystem, particularly biofilms (Demain, 1998).  
Within the complex community of marine invertebrate symbiosis, the secondary 
metabolites may enable the bacteria to provide nutrition and chemical protection in 
exchange for habitat (Lam, 2006; Ward, Bora, 2006). 
 
Historically, any Actinobacteria found in the oceans were believed to originate as spores 
from terrestrial bacteria washed into the sea (Goodfellow, Haynes, 1984).  Over the past 
several years, however, a significant body of research has demonstrated that these 
microbes reside within life forms, the seabed, and the seawater, and require seawater for 
growth (Bull, et al., 2005).  Some of these marine isolates are new strains of known 
genera, but phylogenetic analysis of other isolates has led to the discovery of two new 
genera, Salinispora, (Jensen, et al., 2005) and Marinispora (Kwon, et al., 2006).  These 
unique isolates have been found in all levels of the oceanic ecosystem, from surface 
water to sub-floor sediments, and in symbiotic relationships with marine invertebrates 
(Ward, Bora, 2006).
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II.  CLASSES OF ANTIBIOTICS 
 
Antibiotics are classified according to their mode of action.  One class includes 
antibiotics that interfere with cell wall biosynthesis.  Bacterial cell walls are made of 
peptidoglycan, a rigid meshwork of chains of repeating sugar units cross-linked with 
short peptides.  Gram-positive organisms have a thick peptidoglycan layer.  Gram-
negative organisms, in contrast, have a thin layer surrounded by an outer membrane 
containing lipopolysaccharide. Embedded within the outer membrane are protein 
channels called porins.  By closing these porins, the outer membrane affords an extra 
layer of protection by limiting entry of antibiotics.   The classes of antibiotics which act 
on the cell wall include glycopeptides and β-lactams.  The chemical structure known as a 
β-lactam ring binds to and inactivates peptidoglycan transpeptidase, the enzyme 
responsible for cross-linking the peptides between the sugar backbone chains (Salyers, 
Whitt, 2002).  The result is a weakened cell wall which is then subject to osmotic lysis 
(Figure 1).  Penicillins, cephalosporins, monobactams, and carbapenems make up the β-
lactams.  The glycopeptides vancomycin and teicoplanin also disrupt the integrity of the 
peptidoglycan cell wall by preventing transpeptidation.  These molecules bind to the end 
of the free peptide chains before they can be cross-linked.  Due to their large size, the 
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glycopeptides have a narrow spectrum of activity; they cannot penetrate the porins of the 
gram-negative outer membrane. 
 
 
 
 
 
 
 
Figure 1.  Effect of beta-lactam antibiotics on bacterial cell walls 
Adapted from Cowan, 2012 
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A large class of antibiotics includes drugs that block protein synthesis by binding to 
ribosomes.  Ribosomes are made of ribosomal RNA (rRNA) and protein, in the form of 
two subunits.  In bacteria, the small subunit (30s) consists of approximately twenty 
proteins and a 16s rRNA of 1500 nucleotides.  The large subunit (50s) consists of 
approximately 30 proteins and a 23s rRNA of 2900 nucleotides.  At the surface of the 
large subunit are the A, P, and E codon sites.  It is to the A site that the aminoacyl 
tRNA’s are ushered by the chaperone protein EF-Tu (Walsh, 2003).  Within this structure 
are many potential antibiotic binding sites which will interrupt protein synthesis (Figure 
2). Aminoglycoside antibiotics, represented by streptomycin, kanamycin, and gentamicin, 
also bind to the 30s subunit, but do so in a way that prevents a good fit between the 
subunits and the mRNA, causing a misread of the mRNA.  Chloramphenicol binds to the 
50s subunit so that peptide bonds cannot form between incoming amino acids.  Another 
group, the oxazolidinones, bind in the P site in the peptidyltransferase center, blocking 
the first step of peptide bond formation (Walsh, 2003).  The tetracycline antibiotics bind 
to the 30s subunit to block the binding of aminoacyl tRNA’s at the A site.  The 
macrolides, which include erythromycin, bind and block the exit tunnel for the elongating 
peptide chain.  The macrolide structural elements make up to seven bonds with the 23s 
rRNA of the large subunit.   
 
Another class of antibiotics interferes with cell membranes.  These antibiotics interact 
with membrane phospholipids and either cause a disruption of metabolic processes or  
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Figure 2. Antibiotics that act on the prokaryotic ribosome 
Adapted from Cowan, 2012 
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membrane lysis.  Some antibiotics in this class, such as polymixin, tend to be non-
selective and can damage human membranes as well.  Daptomycin, however, is not as 
toxic and is effective against gram-positive organisms (Cowan, 2012). 
 
The next major class of antibiotics acts by blocking DNA replication and repair.  These 
include quinolones, fluoroquinolones, and novobiocin.  These antibiotics target the 
enzymes that control the coiling and uncoiling of DNA during the replication process.  
Quinolones specifically target topoisomerase II, an enzyme that makes temporary cuts in 
DNA to relieve supercoiling during replication.  When the enzyme cuts the DNA, it binds 
to and holds the free ends.  Quinolones act by binding to this complex, preventing re-
ligation.  This halts the replication forks, signaling cell death (Walsh, 2003). 
 
Rifamycin antibiotics are RNA polymerase inhibitors.  They bind in the DNA/RNA 
tunnel, blocking the elongation of the mRNA chain at the di- or tri-nucleotide stage.  
These antibiotics are currently used primarily for the treatment of tuberculosis (Walsh, 
2003). 
 
The final class of antibiotics includes drugs that target tetrahydrofolate (folic acid) 
synthesis.  These act as competitive inhibitors for key enzymes in the synthesis pathway 
(Figure 3).  Tetrahydrofolate is necessary for proper formation of nucleotides; it carries 
and donates carbon atoms in the nucleotide synthesis reaction (Garrett, Grisham, 2005).  
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Without tetrahydrofolate, a cell cannot replicate DNA and cannot divide.  One of the first 
antibiotics available to the general public, sulfonamide (sulfa), is in this class.  
 
 
 
 
 
 
 
Figure 3  Tetrahydrofolate inhibition 
Adapted from Cowan, 2012 
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III. STATE OF ANTIBIOTIC RESISTANCE 
 
In recent years, infectious disease has been on the rise, and by 2007, was back in the top 
two causes of death in the world, and in the top three in the United States (Spellberg, et 
al., 2008).  An aging population and growing numbers of immunocompromised 
individuals, both with weakened immune systems, contribute to this increase (Boucher, 
2010).  Another is a change in human practices, such as international travel, the 
widespread use of air conditioning, or overcrowding in public housing areas such as 
prisons, slums, or hospitals.  These changes bring individuals into contact with microbes 
that never before had the chance to cause widespread disease.  The largest factor, though, 
has been the microbes themselves.  As the Infectious Diseases Society of America states, 
“It is absurd to believe that we could ever claim victory in a war against organisms that 
outnumber us by a factor of 10
22
, that outweigh us by a factor of 10
8
, that have existed for 
1000 times longer than our species, and that can undergo as many as 500,000 generations 
during 1 of our generations” (Spellberg, et al., 2008).  Very soon after a new drug is 
approved for use, reports of resistance arise.  Most resistance is attributed to overuse of 
the drug, in both humans and livestock.  Because of huge populations and rapid 
generation times, microbes can quickly mutate to accommodate a change in their 
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environment.  They also easily acquire new genes for virulence factors or resistance 
mechanisms from neighboring microbes through lateral gene transfer, and many of those 
genes originate from the same organisms that created the antibiotic as a self-survival 
mechanism (Hopwood, 2007). Resistant organisms are especially prevalent in hospitals, 
where exposure to antibiotics is almost constant.  Resistance can arise quickly due to 
antibiotic selective pressure. 
 
Mechanisms of resistance take many forms (Figure 4).  The first, used by gram negative 
organisms, is limiting access of the antibiotic to the cell by restricting entry through outer 
membrane porins.  Another is the enzymatic destruction or modification of the antibiotic.  
β-lactamase is an enzyme that will hydrolyze penicillin.  Following the development of 
resistance to β-lactam antibiotics, the antibiotics were then modified to include either a β-
lactamase inhibitor like clavulanate, or bulky side groups which blocked the enzyme 
from reaching its active site.  Aminoglycoside antibiotics are rendered inactive when a 
modifying enzyme covalently changes the hydrogen binding site through acetylation, 
phosphorylation, or adenylation (Shahid, Malik, 2005).   
 
Many organisms use active efflux to remove an antibiotic from the cell.  Some of these 
pumps have a narrow specificity, pumping only one antibiotic, others are broad spectrum. 
These broad spectrum pumps are often called multidrug resistant (MDR) pumps, and 
protect the cell from many drugs and other harmful chemicals.  The pumps have 
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hydrophobic transmembrane and hydrophilic cytoplasmic domains and act in a manner 
similar to the proton motive force.  They may also act to export virulence factors such as 
enzymes and toxins.  Screens for pump genes may be used to evaluate culture isolates for 
potential resistance (Ping, et al., 2007).   
 
Another resistance mechanism is to modify or replace an antibiotic’s target.  The 
methicillin resistance gene (mecA) results in a new penicillin binding protein, PBP2A 
(Memmi, et al., 2008), which has a lower binding affinity.  Resistance to macrolide 
antibiotics is achieved by methylation of the peptidyl transferase cavity (Bowers, et al., 
2012).  Widespread use of a vancomycin-like antibiotic in cattle feed and an increase in 
the treatment of opportunistic enterococci infections has led to increased vancomycin 
resistance.  This is brought about by a cassette of five genes (vanR, vanS, vanH, vanX, 
and vanA or B) (Perichon, Courvalin, 2009) that is plasmid borne.  These genes change 
the terminal peptide sequence of peptidoglycan cross links by substituting a lactate 
molecule for the terminal  amino acid alanine.  Vancomycin cannot bind, and the 
peptidoglycan can still cross link.  
  
The final mechanism of resistance is to change metabolic pathways.  Microbes gain 
resistance to sulfonamide/trimethoprim by altering the folic acid synthesis pathway.  This 
most commonly occurs via a mutation in the gene for either ADC synthase, which 
confers sulfa resistance, or dihydrofolate reductase, conferring trimethoprim  
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Figure 4.  Mechanisms of Acquired Drug Resistance 
Adapted from Cowan, 2012 
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resistance (Matthews, et al., 1984).  These modifications render the microbe resistant, but 
still allow for cellular function.  
 
In 2004, the Infectious Disease Society of America (IDSA) issued a policy report titled 
“Bad Bugs, No Drugs:  As Antibiotic R&D Stagnates, a Public Health Crisis Brews”, 
with the intent to raise awareness for the need to renew antibiotic development. (Boucher, 
2004)  In late 2007, the IDSA followed with an update which declared “We are in the 
midst of an emerging crisis of antibiotic resistance for microbial pathogens in the United 
States and throughout the world” (Spellberg, et al., 2008).  This update highlighted a 
global pandemic of antibiotic resistance, the lack of antibiotic discovery, and a need for 
strategies to address antibiotic use.  A few months later, the National Institute of Allergy 
and Infectious Disease (NIAID) identified groups of “superbugs” that are of special 
concern (Peters, et al., 2008).  The first are lung pathogens showing high rates of 
resistance: Streptococcus pneumoniae and multidrug resistant (MDR) and extensively 
drug resistant (XDR) Mycobacterium tuberculosis. 
 
 Streptococcus pneumoniae, the leading cause of community-acquired pneumonia, otitis 
media and meningitis, has become multidrug resistant after developing resistance to 
macrolide antibiotics such as erythromycin.  Erythromycin had been the treatment of 
choice since many S. pneumoniae are now resistant to penicillin (Hidalgo, et al., 2003).  
The genes that confer macrolide resistance, mef E and erm B, are carried by a transposon 
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that also carries tetracycline resistance.  The mefE gene codes for an efflux pump, while 
ermB codes for a methyltransferase resulting in methylation of the ribosomal target 
(Bowers, et al., 2012).  In cases of multidrug resistance, vancomycin has frequently been 
the treatment of choice.  Recently, vancomycin treatment failure has been increasing, 
even though the organism shows susceptibility in drug sensitivity testing.  These 
treatment failures are due to a phenomenon called vanco-tolerance.  Tolerance is defined 
as the ability to survive under antibiotic selective pressure, without evidence of growth 
(Olivares, et al., 2011).  The clinical definition of tolerance is a minimum bactericidal 
concentration (MBC) that is 32X the minimum inhibitory concentration (MIC) (Safdar, 
Rolston, 2006).  The first report of tolerance in S. pneumoniae was in 1999 (Novak, et al., 
1999).  Tolerance is considered the precursor to resistance, which would eliminate one of 
the important antibiotics for multi-drug resistant S. pneumoniae (Hidalgo, et al., 2003).  
Compounding the health threat, these resistance mechanisms are found in serotypes that 
are frequently not included in the heptavalent pneumococcal vaccine.  A newly approved 
13-valent vaccine should change the prevalence of resistance (Bowers, et al., 2012). 
 
 Tuberculosis (TB) is one of the world’s deadliest diseases.  It is believed that one-third 
of the world’s population is infected with Mycobacterium tuberculosis.  Nine million new 
cases and 1.5 million deaths were reported in 2011 (http://www.cdc.gov/tb/statistics/ 
default/htm, http://who.int/tb/publications/global_report/gtbr12_executivesummary.pdf).  
Because of the structure and metabolism of this organism, treatment requires multiple 
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drugs that must be given for six months or longer.  Latent infections, in which the 
Mycobacterium are present in the body, but the patient shows no signs or symptoms, are 
treated with any of three first line drugs, isoniazid, rifampin, and rifapentine, either singly 
or in various combinations for two to eight months (http://www.cdc.gov/mmwr/ 
preview/mmwrhtml/rr5211a1.htm).  TB disease, in which the bacteria are actively 
growing, is treated more aggressively.  The preferred regimen uses four first line drugs- 
isoniazid, rifampin, ethambutol, and pyrazinamide taken daily for eight weeks, followed 
by several options of continuation treatments for another four to seven months 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm).  Because of the rigorous 
nature and the costs involved, this regimen is not always followed, and has led to the 
development of antibiotic resistance.  Tuberculosis resistance arises, not from lateral gene 
transfer, but by normal bacterial mutations that change the antibiotic’s target by adjusting 
functional enzymes, changing cell wall synthesis, or ribosomal proteins (Feuerriegel, et 
al., 2012).  Improper use of antibiotics can cause further mutations due to antibiotic 
selective pressure.  Two levels of resistance have been defined by the World Health 
Organization (WHO).   Multidrug resistance (MDR-TB) is defined as resistance to both 
isoniazid and rifampin.  Extensively drug resistant tuberculosis (XDR-TB) has resistance 
to both isoniazid and rifampin, as well as a fluoroquinolone and one of the three second-
line drugs, amikacin, kanamycin, and capreomycin.  Of greater concern, although 
considered inevitable, are the recent reports of what is being called totally drug resistant 
tuberculosis (TDR-TB), although neither the CDC nor the WHO have accepted that 
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designation.  Three instances of TDR-TB have been reported:  in Italy in 2007 (Migliori, 
et al., 2007), in Iran in 2009 (Velayati, et al., 2009), and most recently, twelve individuals 
in Mumbai, India earlier last year (Udwadia, et al., 2012).  The Indian strain did not 
respond to treatment or susceptibility testing for twelve different antibiotics.  So far three 
of the twelve individuals have died.  The remaining nine are “walking the streets”, 
spreading the disease, because of lack of hospital beds and costs of isolation.  These cases 
may just be scratching the surface, because the lack of medical infrastructure in India 
results in many undiagnosed cases (Loewenberg, 2012). 
 
Enteric anaerobes, as opportunistic pathogens, are another of the “superbug” groups.  
These organisms are normal intestinal biota but are pathogenic when introduced into an 
unusual body site or when there is a disturbance in the gut environment.  Notable 
microbes within this group are Clostridium difficile and Bacteroides fragilis.  Clostridium 
difficile is very resistant to many broad spectrum antibiotics, especially penicillins, 
cephalosporins, and clindamycin.  These antibiotics are administered for some other 
common infection, with a side effect of eradicating much of the normal intestinal biota.  
C. difficile can then proliferate, causing a superinfection, leading to potentially severe 
gastrointestinal distress.  Current treatment for C. difficile infections is either 
metronidazole or vancocin (oral vancomycin), but it is particularly difficult to cure due to 
its spore-forming capability (Louie, et al., 2011).  A new hypervirulent strain has 
emerged, called PCR ribotype 027 (Stabler, et al., 2009).  This strain is associated with 
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increased toxin production, bringing more severe diarrhea, a higher mortality rate, and a 
greater chance of recurrence. 
 
Bacteroides fragilis is common in post-operative infections, particularly abdominal 
surgeries, abdominal perforations, trauma infections, and blood infections (Trevino, et al., 
2012).  Results from five years of surveillance show a gradual overall increase in 
resistance, but it varies from isolate to isolate (Snydman, et al., 2012).  Resistance is 
mediated by a resistance-nodulation division (RND) type multidrug efflux pump, which 
is capable of removing multiple classes of antibiotics (Wexler, 2012).  A recent report 
details resistance to carbapenems (imipenem) due to the production of a metallo-beta 
lactamase (Trevino, et al., 2012). 
  
The last of the “superbugs” is a group of pathogens responsible for most nosocomial 
infections; it has been dubbed the ESKAPE group (Rice, 2008).  ESKAPE is an acronym 
for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumanii, Pseudomonas aeruginosa, and Enterobacter species. 
  
E. faecium is gram positive normal biota of the human gastrointestinal tract and has 
become increasingly resistant to most antimicrobials, including vancomycin.  Resistance 
in E. faecium arises from both mutations and lateral gene transfer from other gut biota 
(Brisson-Noel, et al., 1990).  The plasmid-borne vanA codes for a ligase that changes the 
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terminal peptide sequence of vancomycin’s peptidoglycan target (Perichon, Courvalin, 
2009).  In some areas of the world, the rates of vancomycin resistance is as high as 60% 
(Boucher, et al., 2009).  Individuals most affected are those in intensive care and the 
immunocompromised, and their infections are most likely to be post-operative infections, 
bloodstream, or urinary tract infections arising from inline catheterization.  Catheters and 
other invasive medical devices are prone to biofilm formation.  A functional biofilm 
enhances colonization, provides a matrix for microbial growth through the production of 
an exopolysaccharide (Gordon, Wareham, 2010), and protects the organisms from 
adverse environmental pressures.  The presence of biofilms reduces the efficacy of both 
cleansing techniques and drug regimens, making them harder to remove.  Both 
vancomycin and linezolid are unable to penetrate biofilms formed by E. faecium 
(Bayston, et al., 2012).  Drug resistant E. faecium is disseminating throughout the 
environment, as it has been isolated from both wild and domesticated animals, including 
cats (Ghosh, et al., 2012), poultry (Tremblay, et al., 2011; Sapkota, et al., 2011), fish 
(Araujo, et al., 2011), birds (daSilva, et al., 2011), wolf (Goncalves, et al., 2011), and fox 
(Radhouani, et al., 2011). 
 
Staphylococcus aureus has been a cause of significant morbidity and mortality for 
centuries, despite huge advances in medical care.  In fact, as our knowledge and 
technology increases, the microbe adapts and infections become more complex (Boucher, 
Corey, 2008).  It is mostly implicated in skin and wound infections but has the ability to 
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move deeper into tissues and cause multiple organ infections and bloodstream infections.  
Like the enterococci, it commonly forms biofilms that are resistant to eradication 
(Bayston, et al., 2012).  Methicillin resistant Staphylococcus aureus (MRSA) has become 
a household word in the United States.  While once almost exclusively a nosocomial 
infection (HA-MRSA), community associated (CA-MRSA), or cases arising without 
previous history of hospitalization, is becoming more common (Memmi, et al., 2008).  
MRSA has also been isolated from farm animals (Gharsa, et al., 2012) and found in dairy 
milk (Haran, et al., 2012).  On the horizon are vancomycin intermediate Staphylococcus 
aureus (VISA) and vancomycin resistant Staphylococcus aureus (VRSA).  VRSA is 
believed to be derived by lateral gene transfer of the resistance transposon Tn1546 
carrying the vanA resistance gene cluster from Enterococcus sp. (Perichon, Courvalin, 
2009). There have been thirteen confirmed cases of VRSA in the United States, ten of 
which were confirmed vanA genotype, and additional cases have been reported 
throughout the world.  The last case of VRSA in the United States was in July 2012.  
VISA has been on the rise since 2007, rising from 37 cases in 2007 to 130 reported in 
2012.  Thus far in 2013, 51 cases have been reported 
(http://www.cdc.gov/mmwr/pdf/wk/mm6218md.pdf ).  A new category of vancomycin 
resistance is heterogeneous VISA (hVISA), which is a clinical “mixture” of a susceptible 
strain (MIC <4 mg/mL), with a subpopulation of intermediate organisms with a MIC>8 
mg/mL.  This heterogeneous category is considered the precursor to vancomycin 
intermediate strains (Conly, Johnston, 2002).  Intermediate resistance occurs by a 
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different mechanism than lateral gene transfer.  Organisms have a thickened cell wall, 
which is believed to prevent the vancomycin from penetrating deeply enough to 
compromise the integrity of the peptidoglycan (Conly, Johnston, 2002).  In order to 
identify possible genetic mutations that would lead to the thickened cell wall, Hafer, et al. 
screened the genome of many VISA isolates for possible aberrations and found point 
mutations in many gene loci (Hafer, et al., 2012).  The greater number of mutated genes 
correlated with a higher level of resistance of the organism, but it is not yet known how 
the mutations lead to cell wall thickening or vancomycin resistance.  It has been 
suggested that this intermediate pathway will lead to a resistant phenotype without the 
acquisition of vanA (Tiwari, Sen, 2006).   
 
The remaining four ESKAPE organisms are gram-negative opportunistic pathogens.  
Pseudomonas aeruginosa and Acinetobacter baumanii are ubiquitous environmental 
organisms (Pakyz, et al., 2009; Telang, et al., 2011) while Klebsiella pneumoniae and 
other members of Enterobacteriaceae are normal biota of the human gastrointestinal tract.  
These organisms are transmitted easily from human to human and through every 
environment, and are effective biofilm producers (Gordon, Wareham, 2010).  This 
ubiquitous nature makes them very difficult to eradicate from the medical setting 
(Telang, et al., 2011).  The most common infection sites include the respiratory tract, 
particularly associated with ventilators, the urinary tract usually associated with catheters, 
and wound, bloodstream, and burn infections.  Besides innate resistance due to outer 
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membrane porin modifications, these bacteria have acquired resistance mechanisms for 
nearly every antibiotic available, including drug target mutations, aminoglycoside 
modifying enzymes (Shahid, Malik, 2005), and efflux drug pumps (Gordon, Wareham, 
2010; Sonnet, et al., 2012).  Since 2000, extended spectrum beta-lactamases have 
increased resistance to all beta lactam antibiotics, including all cephalosporins, leaving 
carbapenems as the antibiotic of last resort.  As could be predicted, carbapenem 
resistance has since been on the rise worldwide due to the acquisition of carbapenemase 
genes (Nordmann, Naas, et al., 2011), but of greatest concern is the appearance of a new 
resistance gene.  In 2007, a Swedish patient who had been hospitalized in India was 
diagnosed with a new strain of multidrug resistant K. pneumoniae from a urinary tract 
infection that was resistant to carbapenems.  This new resistance gene was named New 
Delhi metallo-beta-lactamase 1 (NDM-1)( Yong, et al., 2009).  NDM-1 has been 
identified on several different large plasmids, each one also containing a high number of 
resistance genes for other antibiotic classes including cephalosporinase genes, 
aminoglycoside, macrolide, rifampin, and sulfonamide resistance genes (Bonnin, et al., 
2012).  It has spread from Klebsiella and has been isolated in Acinetobacter (Nordmann, 
Poirel, et al., 2011), E. coli (Mulvey, et al., 2011; Bonnin, et al., 2012), and Salmonella 
(Moellering, 2010).  The incidence of carbapenemases has increased world-wide, 
including frequent reports of community acquired cases.  Increasingly worrisome are 
recent reports of NDM-1 being found in the public tap water supplies and in 
environmental water, such as streams, ponds, rivulets, etc., in India (Walsh, et al., 2011) 
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and the identification of NDM-1 isolates in food animals in China (Wang, et al., 2012).  
A new variant, NDM-2, with an identical spectrum of resistance, has also been described 
from a child hospitalized in Cairo, Egypt, and moved to Frankfurt, Germany (Kaase, et 
al., 2011).  Since this first isolation, additional cases have now been reported in other 
countries in the Middle East (Espinal, et al., 2011; Ghazawi, et al., 2012). 
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IV. ISOLATION OF ANTIMICROBIAL METABOLITES 
 
 This acquisition of antibiotic resistance has led researchers on a continuing search for 
new antimicrobial agents, and the new marine Actinobacteria provide promising novel 
metabolites that are under investigation as possible antibiotics.  All the metabolites 
discussed in this review were found using a common sampling and testing protocol, and 
that path from isolation to recovery and identification of antimicrobial metabolites is an 
arduous task.  First, samples are taken from diverse marine habitats.  The samples 
obtained are then cultured in various seawater-based formulations of agar media in 
different environmental conditions, with the intent to optimize the number of unique 
isolates.  Once each isolated microbe colony is identified using 16s rRNA sequencing 
techniques, it is subcultured in agar and liquid media that is once again manipulated with 
various salt and nutrient concentrations and environmental conditions, in order to 
optimize secondary metabolite production.  The generated extracts are collected and 
purified using high-performance liquid chromatography, and the chemical structure of 
each is determined using mass spectroscopy and nuclear magnetic resonance 
spectroscopy.  Sometimes the metabolite is identified as an already known compound 
that may or may not exhibit cytotoxic activity.  Any novel metabolite is then tested for 
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bioactivity against various pathogens, such as MRSA, VRE, Mycobacterium spp., and 
fungi, and cancer cell lines.    
 
There are many limitations to this procedure that result in missing many potential isolates 
and their metabolites.   Marine ecosystems are varied and complex, making a thorough 
sampling nearly impossible.  Despite improvements in culturing techniques, it is 
estimated that 99% of marine microorganisms are uncultured or unculturable, leaving a 
vast number of species that could be exploited if isolated (Maldonado, et al., 2005).  The 
use of 16S rRNA identification improves the chance of isolation of novel species.  
Optimizing growth conditions for the production of secondary metabolites can also be 
difficult.  As can be expected, it may only generate a fraction of possible metabolites, 
since the gene for a metabolite may only be induced under very specific conditions.  
Sequencing technology has revealed that genomes encode far more metabolites than 
originally thought (Jensen, 2010). 
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V. DETERMINATION OF MINIMUM INHIBITORY CONCENTRATION 
 
The test to determine a compound’s ability to inhibit microorganisms is rather 
straightforward; the microbes are grown in a culture medium containing the compound in 
question.  This antibiotic susceptibility test is a broth dilution method.  The antibiotic is 
incorporated into a liquid medium in a series of doubling dilutions, typically 16-8-4-2-1-
0.5 μg/mL.  Each tube is then inoculated with a known quantity of microbes, usually 
5X10e5, and allowed to incubate.  The lowest concentration of antibiotic that displays no 
visible growth is the minimum inhibitory concentration, or MIC (Forbes, 2007).  The 
lower the MIC value seen in testing, the more effective the antibiotic is against that 
microbe.  Traditionally, this is determined visually by observing turbidity in test tubes, 
indicating bacterial growth.  This method requires a large quantity of materials, labor, and 
space to carry out, so it has been modified for use in microdilution testing, which is the 
most widely accepted method as set by Clinical and Laboratory Standards Institute 
(CLSI, 2008).  The method saves media and labor since the microtiter plate typically 
includes preset dilutions of usual antibiotics.  The plate is still read visually but it has 
been enhanced by using colored lights and/or reflective surfaces, decreasing the 
possibility for errors.  Automated systems are also available, in which the microbe 
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inoculum is placed into a “filling tube” which fills a microtiter plate, and the plate is then 
incubated, while a spectrophotometer  measures light transmittance every 15 minutes.  
No change in transmittance indicates no bacterial growth; reduced transmittance indicates 
turbidity from microbial growth, meaning resistance to the tested antibiotic. 
 
A new method showing promising results uses real-time polymerase chain reaction, also 
known as quantitative polymerase chain reaction (Q-PCR), following a short incubation 
period in media that contains a specific quantity of antibiotic.  Q-PCR uses fluorescently 
labeled nucleotides that can be detected by an optical reader.  This is quantitative because 
the more sequence copies in the original sample, the more PCR copies will be made, 
resulting in faster detection of fluorescence.  If the organism is resistant to the antibiotic, 
more bacteria will grow during incubation.  A larger number of bacteria following the 
incubation period results in faster detection of a fluorescent signal from the reaction, 
indicating antibiotic resistance.  Original protocols used species-specific 16s rDNA 
primers for culture-identified pathogens (Rolain, et al., 2004).  An updated method uses a 
single universal 16s rDNA primer against unidentified cells directly isolated from a 
positive blood culture (Beuving, et al., 2011).  The improvement reduces testing time 
from days to hours, since additional subcultures are not needed.  
 
The test results presented in the following tables, the in vitro determination of MIC, is 
only the first step in the determination of the effectiveness of a potential antibiotic for 
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human use.  Before a new compound can be used, it must undergo in vivo tests to 
determine efficacy, toxicity, and pharmacokinetics, which is the ability to penetrate 
tissues to the necessary concentration to achieve a therapeutic effect.  This type of testing 
is carried out by pharmaceutical companies looking to patent and manufacture a new 
product (Gootz, 1990).  
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VI. EVALUATION OF NOVEL MARINE METABOLITES 
 
Isolated from the Sea of Japan at a depth of 289 meters (the Abyss) (Nicolau, Harrison, 
2007), new strains of the marine Actinomycete genus Verrucosispora have yielded two 
new classes of cytotoxic metabolites, the proximicins and the abyssomicins.  Strain MG-
37 yielded three related proximicins, A, B, and C, and strain AB-18-032, now with the 
proposed name “Verrucosispora maris”, (Fiedler, et al., 2008) yielded proximicin A, B 
and C, and abyssomicins. 
 
Proximicins A, B, and C are structural analogues of the antibiotics netropsin and 
distamycin (Schneider, et al., 2008) (Figure 5) that exhibit strong antitumor (Fiedler, et 
al., 2008) and moderate antibacterial activity (Brucoli, et al., 2012) (Table 1).  Netropsin 
and distamycin inhibit DNA replication by binding directly to the minor groove of the 
DNA molecule but have never gained widespread use because of lack of selectivity.  It 
was believed the proximicins would have a similar mode of action, but this was 
disproven by comparing the DNA denaturation curves of netropsin, distamycin, and the 
proximicins.  Untreated DNA denatured at a mean temperature of 45°C.  Due to the 
binding of netropsin and distamycin, the denaturation temperature is shifted higher to 
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78°C and 60°C, respectively.  Treatment with the proximicins did not alter the 
denaturation temperature of DNA, indicating these molecules do not bind to DNA 
(Schneider, et al., 2008).  To determine how the proximicins affect cell division, cell 
cycle analysis was performed.  Gastric adenocarcinoma (AGS) cells were stained with 
propidium iodide and analyzed using a cell counter to obtain a baseline percentage of 
cells in each phase of the cell cycle.  AGS cells were then incubated with netropsin, 
distamycin, or proximicin C, and analyzed as above to determine any alteration in the cell 
cycle.  While both netropsin and distamycin caused an accumulation of cells in the G2/M 
phase, proximicin C produced an accumulation of cells in G1.  This data led to an 
evaluation of cell cycle regulatory proteins for the transition of G1 to S phase, cyclin E, 
p53, and p21.  AGS cells were incubated with proximicin C and cell proteins were 
Western blotted, revealing an upregulation of both p53 and p21.  This exact mechanism 
of action of the proximicins on the cell cycle remains under investigation (Schneider, et 
al., 2008).  
 Table 1  Antimicrobial activity (MIC, μg/mL) of proximicin B 
and C 
   Organism B C 
S. aureus ATCC29623 8 >256 
S. aureus EMRSA-16 8 >256 
S. aureus SA11998 4 >256 
S. aureus EMRSA-15 8 >128 
Enterococcus faecalis 4 >128 
E. coli >128 >128 
 
Adapted from Brucoli, 2012 
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A group of secondary metabolites from “Verrucosispora maris” have been named 
abyssomicins.  To date, abyssomicins B through H have been identified, but only 
abyssomicin C and its isomer, atrop-abyssomicin C (Figure 6), have shown effective 
antibiotic activity (Bister, et al., 2004). Their mode of action is inhibition of the 
Figure 5.  Structures of Netropsin(1), Distamycin(2), Proximicin A(3), Proximicin B(4), 
and Proximicin C(5).  The double helix illustrates the binding of netropsin into DNA.  
Adapted from Schneider, et al., 2008 
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tetrahydrofolate biosynthesis pathway by blocking the first step, conversion of 
chorismate to pABA.  Two enzymes catalyze the reaction, 4-amino-4-deoxychorismate 
(ADC) synthase and ADC lyase (Keller, et al., 2007).  Abyssomicin C mimics chorismate 
(Figure 7) and irreversibly binds to a cystein near the active site of PabB, a subunit of 
ADC synthase.  This binding is dependent upon the presence of an enone Michael 
acceptor, which the other abyssomicins lack.  An enone, a double bonded carbon adjacent 
to the double bonded oxygen of a ketone, is able to accept electrons from another 
molecule when binding.  Here the enone participates in a Michael reaction with a sulfur 
residue on the cysteine.  (Keller, et al., 2007).  Antimicrobial testing was carried out 
against methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant 
Staphylococcus aureus (VRSA), Mycobacterium bovis, and Mycobacterium tuberculosis, 
and showed a strong inhibitory effect (Table 2).  This metabolite could prove to be a very 
effective antibiotic since its mechanism is highly selective for prokaryotic organisms. 
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         4: atrop-abyssomicin C 
Figure 6. Structures of Abyssomicins B, C, atrop-C, and D.                             
Adapted from Nicolaou, Harrison, 2007 
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A marine isolate was found from a sediment sample taken from Mission Bay in San 
Diego.  After characterization, it was determined to be unique and was suggested to be 
placed in a new genus with the proposed name “Marinispora”.  The crude fermentation 
extract was found to be a rich source of potential new antibiotics (Kwon, et al., 2006).  
Since that time, more than 20 new strains of “Marinispora” have been identified from 
Table 2  Antimicrobial activity (MIC, μg/mL) of abyssomicin C and atrop-abyssomicin C 
    Organism Abyssomicin C atrop-Abyssomicin C 
 MRSA 4A 3.5B 
 MDR-VRSA 13A
 
NT 
 Mycobacterium smegmatis 10C 20C 
 Mycobacterium bovis 2.5C 5C 
 Mycobacterium tuberculosis 1.2C 2.5C 
 
Figure 7.  Structure of chorismate; compare to the structure of 
abyssomicins in figure 6.  Adapted from Bister, et al., 2004 
Abbrev: MDR-Multi-drug resistant.  NT-Not tested. Adapted from:  A-from Bister, et al., 2004  B- from Nicolaou, 
Harrison, 2007.  C- from Freundlich, et al., 2010 
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diverse locations, (Kwon, et al., 2009) and several metabolites have been analyzed.  
Three metabolites are reported to have cytotoxic properties.  The first of these 
metabolites was named marinomycin.  The four unique isolates (A-D) are characterized 
as polyene macrodiolides (Kwon, et al., 2006).  Macrodiolides are structurally related to 
the macrolide class of antibiotics but are different in function.  Macrolides have ether 
functional groups that bind to the 50s portion of the bacterial ribosome, halting protein 
synthesis, where polyenes, molecules with stretches of alternating carbon double bonds, 
are hydrophobic molecules that integrate into the phospholipids of cell membranes; the 
antifungal drug amphotericin B is in this class (Figure 8).  The structure of the 
marinomycins is a dimer composed of two identical 29 carbon subunits (Figure 9).  Note 
the similarity to amphotericin B, with the stretches of polyene chains.  With this 
structure, one would expect the marinomycins to act as membrane active antifungals, but 
they actually showed very weak activity.  Marinomycin A was a potent antibiotic when 
tested against MRSA and VRE (Table 3) and also had impressive results in the NCI panel 
of 60 cancer cell lines, particularly against melanoma cell lines.  The mechanism of 
action has not yet been determined, but would be expected to be membrane active.  The 
large size of this molecule may also hinder its usefulness as a marketable pharmaceutical.  
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Table 3  Antimicrobial activity (MIC, μM) of Marinomycins A-D 
      Organism  A B C D 
 MRSA 0.13 0.25 0.25 0.25 
 VREF 0.13 NA NA NA 
 Candida albicans 7.8 NA NA NA 
 
Figure 8.  Amphotericin B, a polyene.  
Adapted from Cowan, 2012 
Abbrev. VREF-Vancomycin-resistant Enterococcus faecium, NA-no activity.   
 
Adapted from Kwon, et al., 2006. 
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Figure 9.  Structures of Marinomycins A, B, and C.  
Adapted from Nicolaou, et al., 2007 
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Also derived from “Marinispora” are the metabolites Lipoxazolidinones A, B, and C 
(Macherla, et al., 2007).  They are the first natural source antibiotic of the oxazolidinone 
class, currently represented by linezolid (Zyvox). These block protein synthesis by 
binding to the peptidyltransferase center of the 70s ribosome.  The active portion of these 
molecules is the oxazolidinone ring, a five membered ring containing nitrogen with a 
ketone group attached (Figure 10), which binds in such a way as to prevent transfer of N-
formylmethionine-transfer-RNA from the A site to the P site. (Phillips, et al., 2003; Aoki, 
et al., 2002) The lipoxazolidinones underwent antimicrobial testing against both Gram 
positive and Gram negative organisms.  Linezolid was also tested for comparison. The 
results of the testing are shown in Table 4.   Lipoxazolidinones A, B, and C displayed 
activity at the same levels as linezolid, with effective inhibition of gram-positive 
organisms, and limited activity against gram-negative organisms.  The large size of the 
molecule limits the passage through outer membrane porins.  
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Table 4  Antimicrobial activity (MIC, μg/mL) of Lipoxazolidinones A-C and 
Linezolid 
     Organism A B C Linezolid 
MRSA 1 1.5 3 1.5 
MDR S. epidermidis 0.5 0.8 NT 1 
Penicillin resistant S. pnuemoniae 4.7 6 NT 1 
VREF 1.8 1.5 NT 4 
Haemophilus influenzae 12 16 5 12 
Escherichia coli >32 >32 >32 >32 
 
Figure 10.  Structures of Lipoxazolidinones A(1), B(2), (3), and Linezolid.  
Adapted from Macherla, et al., 2007. 
MDR-multi-drug resistant.  NT-not tested.                      
Adapted from Macherla, et al., 2007 
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Lynamicins A-E were isolated from Marinispora and identified as chlorinated bisindole 
pyrroles (Figure 11).  Bisindole refers to the pair of double ring structures with the 
chlorine atoms attached, and pyrrole is the nitrogenous ring structure they are attached to. 
The difference between lynamicins A through E is the number of chlorine atoms on the 
indole groups.  Lynamicin E has the fewest chlorine substitutions; it has only one.  They 
do not fall into any previously described antibiotic class.  Their mode of action remains to 
be found, although it appears to be linked to chlorination (McArthur, et al., 2008), since 
lynamicin E had the highest MIC value of the five metabolites tested.  When assayed for 
antibiotic activity, the compounds showed potency against a number of microorganisms, 
including MRSA and VREF (Table 5). 
 
    
 
 
Table 5  Antimicrobial activity (MIC, μg/mL) of Lynamicins A-E 
  
      Organism A B C D E 
MRSA 2 1 1.5 3 12 
MDR S. epidermidis 4 1 1 4 >32 
Penicillin resistant S. pnuemoniae 24 8 20 20 >32 
VREF 8 2 2 8 >24 
Haemophilus influenzae 12 6 6 8 >32 
Escherichia coli 16 6 6 >32 >32 
MDR-multi-drug resistant.                 
Adapted from McArthur, et al., 2008 
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Figure 11.  Lynamicins A-E, 1-5.   
Adapted from McArthur, et al., 2008 
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Another new group of sea water-dependant actinobacteria was discovered in marine 
sediments and was determined to be a unique genus that was named Salinispora (Jensen, 
et al., 2005).  To date, three species have been formally described, S. pacifica, S. 
arenicola, and S. tropica.  Salinispora species have generated much excitement as a 
source of secondary metabolites (Jensen, et al., 2007).  Four metabolites have so far been 
identified from S. pacifica, cyanosporasides (Oh, et al., 2006), salinosporamide K 
(Eustaquio, et al., 2011), salinipyrones, and pacificanones (Oh, et al., 2008).  All these 
were tested for bioactivity, but none had a cytotoxic or antibiotic effect.  The six 
identified metabolites of  S. arenicola have been the subject of even greater study.  The 
arenicolides (Williams, et al., 2007), saliniketals (Williams, Asolkar, et al., 2007), 
cyclomarins and cyclomarazines (Schultz, et al., 2008) were not bioactive, but two 
effective antibiotics have been isolated, arenimycin and rifamycins B and SV.    
Arenimycin has been identified as a quinone derivative (Asolkar, et al., 2010)(Figure 12).  
Its mode of action has not been found, but it has potent antibiotic activity against gram 
positive pathogens, Mycobacterium (Table 6), and a human adenocarcinoma cell line. 
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Table 6  Antimicrobial activity (MIC, μg/mL) for 
Arenimycin  
  Organism MIC 
Rifampin and methicillin resistant S. aureus 1.06 
MRSA (5158) 0.53 
MRSA (5085) 1.03 
MRSA (5167) 0.13 
MRSA (5177) 0.05 
MRSA (5218) 1 
Staphylococcus epidermidis 0.05 
Staphylococcus saprophyticus 0.1 
Enterococcus faecalis 0.06 
Enterococcus faecium 0.25 
VREF >8 
Mycobacterium bacille (Calmette Guerin) 1 
Figure 12.  Structure of arenimycin.                               
Adapted from Asolkar, et al., 2010. 
Adapted from Asolkar, et al., 2010 
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Rifamycins B and SV (Figure 13) are known antibiotics from the soil bacteria 
Amycolatopsis mediterranei and have been the basis for antibiotics in the rifampin 
family. The discovery of the rifamycin gene clusters in the unrelated species S. arenicola 
provides a new source for this important antibiotic (Kim, et al., 2006).  Rifamycin binds 
to bacterial RNA polymerase molecules and prevents the lengthening of the mRNA 
chain. Because of their size, they are only useful for gram positive organisms, as they are 
too large to pass through the porins of the gram negative membrane. 
   
None of the metabolites from Salinispora tropica displayed antibiotic activity (Jensen, et 
al., 2007), however, salinosporamide A  (Figure 14) has potent cytotoxic activity, and, 
under the trade name Marizomib, is currently in clinical trials for the treatment of many 
cancers, including multiple myeloma, lymphoma, leukemia, glioma, colon, and 
Figure 13.  Structures of the rifamycins.    
Adapted from Kim, et al., 2006. 
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pancreatic (Potts, et al., 2011).  Marizomib is an inhibitor of the 20s subunit of the 
proteasome (Williams, et al., 2005).  Because of this strong cytotoxic effect, 
salinosporamide A was tested and found to be effective against Plasmodium falciparum, 
the causative agent of malaria (Prudhomme, et al., 2008), and Trypanosoma brucei, the 
causative agent of African sleeping sickness (Steverding, et al., 2012). 
   
 
 
 
Figure 14  Structure of Salinosporamide A.  
 Adapted from Jensen, et al., 2007 
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VII. THE NEXT STEPS 
 
The compounds discussed here are in the earliest stages of analysis.  The inhibition of 
microbial growth in microtiter wells is the first step of a very long process to bring new 
drugs to market (reviewed by Gootz, 1990).  A pharmaceutical developer will evaluate 
the potential marketability of  a compound based on what is known about the structure 
and mechanism of action.  Then culture and purification systems must be optimized to 
provide the large quantities of compounds needed for testing.  Analysis then moves from 
in vitro to in vivo, starting with administration to rodents.  A compound must undergo 
studies that characterize its mechanism of action and extensively assess its safety and 
efficacy in animals.  A new metabolite is rarely marketed in its original form due to 
deficits in activity or potency, in vivo stability or pharmacokinetics, or an unacceptable 
safety profile as determined in animal studies.  Many metabolites are manipulated 
chemically to assess the changes in biological activity.  These are called structure-activity 
relationships (SAR).  Chemical substitutions around the biological active site can 
improve the deficits mentioned above, the safety profile and prevent the activity of 
resistance mechanisms.  All the various pharmacokinetic variables for each compound 
are tested.  Additional animal studies predict the antibiotic’s effects in humans and  are 
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then used to determine how well the agent will cure an infection.  These are called in vivo 
protection studies and they help determine the proper effective dose that protects 50% of 
the animals from death due to infection (PD 50).  Toxicity studies are also included to 
assess acute and chronic dosing schedules with regard to safety, reproductive effects, 
organ dysfunction (especially liver and kidney), blood abnormalities, carcinogenicity, 
behavioral changes and lethality.  There are several factors that can limit the results of 
animal testing. Some of these factors are practical in nature.  Animal testing is more 
expensive, and is subject to increased ethics scrutiny, which keeps the numbers of trials at 
the bare minimum needed for proper data collection.  Time is another practical constraint; 
the shorter lifespan of small mammals limits true long-term toxicology and 
carcinogenicity studies.  Other factors are biological in nature.  Small mammals generally 
metabolize faster, allowing them to breakdown and eliminate drugs more rapidly.  There 
are also different permeability rates based on different cell transport mechanisms.  To 
make accurate predictions despite these differences, researchers rely on animal models, 
established protocols that are based on animal and human comparative data derived from 
years of previous research of similar drugs (Gootz, 1990).  Researchers must choose 
which animal model will be the best fit for their drug.  
 
Successful safety studies allow the drug to be considered for clinical trials, and the Food 
and Drug Administration (FDA) website details all the requirements for this process.  
Every pharmacological variable is carefully detailed for the first step, the investigational 
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new drug (IND) application.  The IND must contain data in three general areas, animal 
pharmacological and toxicology studies as discussed above, manufacturing information, 
to ensure the production company can adequately and safely produce enough drug for 
trials, and clinical protocols and investigator information to determine the planned 
studies, the risks involved, and to ascertain the qualification of the investigator 
(http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandappro
ved/approvalapplications/investigationalnewdrugINDapplication/defaulthtml).  After the 
IND is filed, the developer must wait 30 days before starting trials to allow the FDA to 
review the application. 
 
The antimicrobial then begins Phase 1 investigation, which involves the first 
administration to humans.  The total number of healthy volunteers required is 
approximately 100.  The goal of Phase 1 is not to determine effectiveness, but to establish 
metabolic and pharmacologic action in humans along with possible toxicological effects.  
The generated data are used to design effective Phase 2 studies.  Phase 2 studies are 
controlled studies to evaluate the effectiveness of the drug and to determine the short 
term side effects.  The several hundred subjects are individuals whose infections are non-
life threatening. Phase 3 trials are performed after preliminary effectiveness is determined 
in Phase 2 and are designed to gather additional information about effectiveness, safety 
and dosage.  This testing requires several years and several thousand subjects. 
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Following the completion of Phase 3 studies, the pharmaceutical company must organize 
all its data and submit the New Drug Application (NDA) to the FDA for review.  The 
NDA will encompass information on manufacturing specifications, stability and 
bioavailability data, method of analysis of dosage forms, packaging and labeling and any 
additional toxicology studies 
(http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandappro
ved/approvalapplications/newdrugapplicationNDA/default.html).  The review takes from 
18 months to two years to complete, and then the antibiotic is permitted to be marketed in 
the United States.  
 
Since microbes will always find new resistance mechanisms, humans must continue to 
hunt for new antibiotics.  The marine Actinobacteria are an untapped source for these 
new compounds, and will hopefully yield some marketable pharmaceuticals.  
Undoubtedly, there are countless microbial species just waiting to be discovered within 
the vast oceans, and current sampling techniques only identify a small fraction.  As we 
continue to refine molecular techniques, such as 16S rRNA identification, our discoveries 
will increase.  Additionally, genomic analysis can lead to the discovery of biosynthetic 
pathways for even more metabolites than can be found through culture techniques and 
can give clues as to the growth conditions required for the production of said metabolites.  
Isolation of such genetic sequences can also allow them to be utilized in recombinant 
technology to mass-produce large quantities.   
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